Dynamic Technology Lab Private Ltd Acquires New Position in United Therapeutics Corporation $UTHR

Key Points

• Dynamic Technology Lab Private Ltd has acquired 2,812 shares of United Therapeutics Corporation, valued at approximately $867,000, as per a recent 13F filing.
• Insider trading activity includes Richard Giltner selling 3,036 shares for around $879,225.60, and Paul A. Mahon selling 11,000 shares for approximately $4.24 million.
• Analysts maintain a consensus rating of "Moderate Buy" for United Therapeutics, with an average target price estimated at $429.62.

Dynamic Technology Lab Private Ltd purchased a new stake in United Therapeutics Corporation (NASDAQ:UTHR - Free Report) during the first quarter, according to the company in its most recent filing with the SEC. The firm purchased 2,812 shares of the biotechnology company's stock, valued at approximately $867,000.

A number of other hedge funds also recently made changes to their positions in UTHR. Vaughan Nelson Investment Management L.P. acquired a new position in shares of United Therapeutics in the 1st quarter valued at $101,354,000. Nuveen LLC acquired a new position in shares of United Therapeutics in the 1st quarter valued at $83,533,000. Amundi boosted its holdings in shares of United Therapeutics by 198.8% in the 1st quarter. Amundi now owns 350,193 shares of the biotechnology company's stock valued at $107,635,000 after purchasing an additional 232,988 shares during the last quarter. GAMMA Investing LLC lifted its holdings in shares of United Therapeutics by 29,415.2% during the 1st quarter. GAMMA Investing LLC now owns 221,954 shares of the biotechnology company's stock valued at $68,422,000 after acquiring an additional 221,202 shares in the last quarter. Finally, Invesco Ltd. lifted its holdings in shares of United Therapeutics by 46.1% during the 1st quarter. Invesco Ltd. now owns 465,115 shares of the biotechnology company's stock valued at $143,381,000 after acquiring an additional 146,664 shares in the last quarter. Institutional investors and hedge funds own 94.08% of the company's stock.

Analyst Upgrades and Downgrades

UTHR has been the topic of several recent research reports. Morgan Stanley reduced their target price on shares of United Therapeutics from $348.00 to $328.00 and set an "equal weight" rating on the stock in a report on Thursday, July 10th. Cantor Fitzgerald lifted their target price on shares of United Therapeutics from $405.00 to $525.00 and gave the company an "overweight" rating in a report on Wednesday. JPMorgan Chase & Co. reduced their target price on shares of United Therapeutics from $350.00 to $330.00 and set an "overweight" rating on the stock in a report on Tuesday, July 8th. Wells Fargo & Company lifted their target price on shares of United Therapeutics from $295.00 to $414.00 and gave the company an "equal weight" rating in a report on Wednesday, September 3rd. Finally, Oppenheimer lifted their target price on shares of United Therapeutics from $510.00 to $575.00 and gave the company an "outperform" rating in a report on Friday, September 5th. Nine analysts have rated the stock with a Buy rating and four have given a Hold rating to the company's stock. According to MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $438.85.

Insider Buying and Selling

In other news, COO Michael Benkowitz sold 11,375 shares of the business's stock in a transaction dated Tuesday, September 9th. The shares were sold at an average price of $397.41, for a total value of $4,520,538.75. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Jan Malcolm sold 700 shares of the business's stock in a transaction dated Tuesday, September 9th. The stock was sold at an average price of $400.29, for a total transaction of $280,203.00. Following the completion of the sale, the director directly owned 520 shares of the company's stock, valued at $208,150.80. The trade was a 57.38% decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 128,816 shares of company stock worth $45,836,113. 10.30% of the stock is currently owned by insiders.

United Therapeutics Trading Up 0.0%

UTHR stock traded up $0.18 during trading on Friday, reaching $405.02. The stock had a trading volume of 626,423 shares, compared to its average volume of 565,230. United Therapeutics Corporation has a 1-year low of $266.98 and a 1-year high of $436.95. The company has a market capitalization of $18.27 billion, a P/E ratio of 15.81, a PEG ratio of 6.05 and a beta of 0.62. The firm has a fifty day moving average price of $316.32 and a 200 day moving average price of $307.23.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last issued its quarterly earnings data on Wednesday, July 30th. The biotechnology company reported $6.41 EPS for the quarter, missing analysts' consensus estimates of $6.80 by ($0.39). The firm had revenue of $798.60 million during the quarter, compared to analyst estimates of $802.13 million. United Therapeutics had a return on equity of 18.73% and a net margin of 40.36%.The business's quarterly revenue was up 11.7% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $5.85 EPS. Sell-side analysts predict that United Therapeutics Corporation will post 24.48 EPS for the current year.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.